DNA Binding and Anticancer Activity of Novel Cyclometalated Platinum (II) Complexes

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

DNA Binding and Anticancer Activity of Novel Cyclometalated Platinum (II) Complexes

Anti-Cancer Agents in Medicinal Chemistry, 15(1): 107-114.

Author(s): Roghayeh Mohammadi, Reza Yousefi, Marzieh Dadkhah Aseman, S. Masoud Nabavizadeh and Mehdi Rashidi.

Affiliation: Protein Chemistry Laboratory (PCL), Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran.


This study describes anticancer activity and DNA binding properties of two cyclometalated platinum (II) complexes with non-leaving lipophilic ligands; deprotonated 2-phenylpryidine (ppy): C1 and deprotonated benzo[h] quinolone (bhq): C2. Both complexes demonstrate significant anticancer activity and were capable to stimulate Caspase-III activity in Jurkat cancer cells. The results of Acridine orange/Ethidium bromide(AO/EtB), along with those of Caspase-III activity suggest that these complexes can induce apoptosis in the cancer cells. Moreover, C1 with flexible chemical structure indicates considerably higher anticancer activity than C2 which possesses a higher structural rigidity. Additionally, C2 represents a complex which is in part inducing cancer cell death due to the cell injury (necrosis). The absorption spectra of DNA demonstrate a hypochromic effect in the presence of increasing concentration of these complexes, reflecting DNA structural alteration after drug binding. Also, EtB competition assay and docking results revealed partial intercalation and DNA groove binding for the metal complexes. Overall, from the therapeutic point of view, ppy containing platinum complex (C1) is a favored anticancer agent, because it induces signaling cell death (apoptosis) in cancer cells, and lacks the necrotic effect.


Anticancer activity, absorption spectra, caspase-III activity, cyclometalated platinum (II) complexes, molecular docking.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
Issue Number: 1
First Page: 107
Last Page: 114
Page Count: 8
DOI: 10.2174/1871520614666141203143543

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science